125101-79-3

Upstream product

• 125101-73-7 1,1-dibenzyloxy-4-phenyl-3-cyclohexen-2-one 

Downstream Products

• 125101-83-9 4-benzyloxy-3-methoxybiphenyl 
• 37055-79-1 4-hydroxy-3-methoxybiphenyl 

Relevant academic research and scientific papers

WB4101-related compounds: New, subtype-selective α1- adrenoreceptor antagonists (or inverse agonists?)

Our previous structure-affinity relationship study had considered the enantiomers of the naphthodioxane, tetrahydronaphthodioxane, and 2-methoxy-1-naphthoxy analogues (compounds 1, 3, and 2, respectively) of 2-(2,6-dimethoxyphenoxyethylaminomethyl)-1,4-be

Method of treatment for prostatic cancer

Disclosed is a new treatment for men with prostatic cancer involving combination therapy of a 5α-reductase inhibitor, i.e., a 17β-substituted 4-azasteroid, a 17β-substituted non-azasteroid, 17β-acyl-3-carboxyandrost-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylamino-phenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an antiandrogen, i.e. flutamide. Pharmaceutical compositions useful for treatment are also disclosed.

Method of treatment for benign prostatic hyperplasia

Disclosed is an improved treatment for men with benign prostatic hyperplasia (BPH), involving combination therapy of a 5α-reductase inhibitor, e.g. a 17β-substituted 4-azasteroid, a 17β-substituted non-azasteroid, 17β-acyl-3-carboxy-androst-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an α1 -adrenergic receptor blocker, i.e., terazosin. The combination provides therapy at the molecular level for the underlying cause of the disease as well as providing symptomatic relief. Pharmaceutical compositions useful for treatment are also disclosed.

New catechol type non-steroidal drugs as 5-alpha reductase inhibitors

Described are new non-steroidal drugs for treatment of benign prostatic hyperplasia and other disorders mediated by high 5-alpha reductase activity, or high dihydrotestosterone levels, and other conditions of hyperandrogenic stimulation

A new entry to the synthesis of 1,2-benzenediol congeners

1,2-Benzenediols were synthesized via 1,1-bis(ethylthio)-3-cyclohexen-2-one derivatives, which were prepared by condensation of 1,1-bis(ethylthio)-2-propanone with Mannich bases. Regioselective preparation of their monoethers was also achieved.

A NEW ENTRY TO 1,2-BENZENEDIOL CONGENERS

1,2-Benzenediols and their monoethers were efficiently prepared from α,α-bis(ethylthio)cyclohexenones which were constructed by the C3+C3 annulation of 1,1-bis(ethylthio)propan-2-one and the Mannich bases. KEYWORDS 1,2-benzenediol; aromatic synthesis; annulation; aromatic compound; acetal